What is the main business of KCR?

The main business activity of KCR focuses on research and experimental development in natural sciences and engineering.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on September 28, 2007.

Where is the headquarters located?

The headquarters is located at: ul. Prosta 68, 00-838 Warszawa.

What is the share capital?

The share capital of the company is PLN 506,246 (approx. $136,749).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2023 to December 31, 2023.

How much revenue was generated?

The company reported a revenue of $43,596,035 in 2023, which is a decrease of 20.9% compared to 2022.

Yes, the company recorded a net profit of $489,333 in 2023, meaning the company decreased its profit by 91.4%.

Which cost dominates operating expenses?

The largest operating cost category falls under employee remuneration. This category amounted to $25,546,333 in 2023, representing 61% of all operating expenses.

KCRS.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2007-09-28

Share capital

506 246,20 PLN

Activity description

ICON plc provides clinical research outsourcing services for biotech and small to mid-sized biopharma companies. It supports programs from early-phase design through market access, and offers consulting, advisory services, and tailored clinical development. The company also focuses on areas such as genomic breakthroughs, first-in-class immunotherapies, and drug development in APAC and China.

Registered address

ul. Prosta 68, 00-838 Warszawa, Poland

Website

kcrcro.com

Social media

Electronic delivery address

AE:PL-89455-60296-DJADD-26

Financials

The financial statement for 2024 has not yet been filed with the Financial Document Repository (past deadline).

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2023.

Results vs industry

Revenue

This companyUSD 43.60mMedianUSD 133.91kAverageUSD 4.65m

Net profit

This companyUSD 489.33kMedianUSD -54.78AverageUSD 310.10k

Operating costs

This companyUSD 42.03mMedianUSD 175.72kAverageUSD 4.46m

Assets

This companyUSD 27.86mMedianUSD 254.44kAverageUSD 8.12m

Industry

Bank accounts

Registered as a VAT taxpayer on 2001-12-04. Active

Citi Handlowy (Bank Handlowy w Warszawie)
27 1030 1508 0000 0008 2416 4836
Citi Handlowy (Bank Handlowy w Warszawie)
66 1030 1508 0000 0008 2416 4328
mBank
07 1140 1977 0000 2292 5600 1002

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

MSiG notices

Publication date	Event
May 7, 2024	Commercial Companies Code notice
Nov 21, 2019	Financial statement published
Aug 1, 2018	Bankruptcy notice
Nov 17, 2014	Bankruptcy notice
Nov 3, 2014	Financial statement published

Public aid

No public aid cases recorded in the last 10 years.

European Funds

Start	Project	EU co-financing	Programme
2010-07-01	Health-f2-2010-261358/paddington	$1.8M$1,772,643	FP7 Cooperation

Tenders

No recorded participation in tenders.

Trademarks

KCR currently holds no active trademarks with the Polish Patent Office. 6 marks have expired or were not registered. The first mark was filed in 2013.

Mark	Number	Classes	Status	Protected until
KCR	Z.419992	35, 42	Expired	–
KCR	Z.419993	35, 42	Expired	–
KCR KNOWLEDGE / COMMITMENT / RESULTS	Z.419994	35, 42	Expired	–
KCR KNOWLEDGE COMMITMENT RESULTS	Z.419995	35, 42	Expired	–
KNOWLEDGE COMMITMENT RESULTS KCR	Z.419996	35, 42	Expired	–

Mark	Protected until
KCR	–
KCR	–
KCR KNOWLEDGE / COMMITMENT / RESULTS	–
KCR KNOWLEDGE COMMITMENT RESULTS	–
KNOWLEDGE COMMITMENT RESULTS KCR	–

Authorized Representatives

Emer Lyons – Management Board Member

Simon Hollywood – Management Board Member

Simon Holmes – Management Board Member

Manner of representation

Each member of the management board is authorized to make declarations of will on behalf of the company independently.

Supervisory board

Diarmaid Cunningham – Supervisory Board Member

Julian Hayes – Supervisory Board Member

James Houlihan – Supervisory Board Member

Beneficial owners

Person	Rights

Subsidiaries

	Name	Share value	Stake
	Curandussp. z o.o.	13,506.21 USD	100%
	KCR Placementsp. z o.o.	13,506.21 USD	100%

Competitors

Name	Revenue	Website
Polpharma BiologicsS.A.	$19,057,541.37	polpharmabiologics.com
ArdigenS.A.	$12,513,309.89	ardigen.com
Sidlysp. z o.o.	$4,977,649.42	sidly.eu

Change history

Date	Event
2025-04-28	Address change (Postępu 6, 02-676, Warszawa → Ul. Prosta 68, 00-838, Warszawa)
2025-04-28	PKD change (Removed: 46.46.Z, 69.20.Z, 70.10.Z, 70.21.Z, 70.22.Z, 72.19.Z, 73.20.Z, 82.30.Z, 85.60.Z, 86.90.E; Added: 69.20.A, 69.20.B, 70.10.B, 70.20.Z, 72.10.Z, 73.30.B)
2024-07-18	Share capital change (571,666.20 PLN → 506,246.20 PLN)
2018-05-21	Share capital change (700,000.00 PLN → 571,666.20 PLN)
2015-01-12	PKD change (Removed: 46.18.Z, 46.19.Z, 85.59.B)

FAQ

Last updated: 2026-03-22